Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
J Diabetes Complications ; 35(3): 107843, 2021 03.
Article de Anglais | MEDLINE | ID: mdl-33419633

RÉSUMÉ

AIMS: Pancreatic beta-cell lipo-dysfunction decreases insulin secretion and predisposes to the development of type 2 diabetes. Through targeted Pex11ß knockdown and peroxisome depletion, our aim was to investigate the specific contribution of peroxisomes to palmitate mediated pancreatic beta-cell dysfunction. METHODS: MIN6 cells were transfected with probes targeted against Pex11ß, a regulator of peroxisome abundance, or with scrambled control probes. Peroxisome abundance was measured by PMP-70 protein expression. 48 h post transfection, cells were incubated with 250 µM palmitate or BSA control for a further 48 h before measurement of glucose stimulated insulin secretion and of reactive oxygen species. RESULTS: Pex11ß knockdown decreased target gene expression by >80% compared with the scrambled control (P<0.001). This led to decreased PMP-70 expression (p<0.01) and a 22% decrease in peroxisome number (p<0.05). At 25 mM glucose, palmitate treatment decreased insulin secretion by 64% in the scrambled control cells (2.54±0.25 vs 7.07±0.83 [mean±SEM] ng/h/µg protein; Palmitate vs BSA P<0.001), but by just 37% in the Pex11ß knockdown cells. Comparing responses in the presence of palmitate, insulin secretion at 25 mM glucose was significantly greater in the Pex11ß knockdown cells compared with the scrambled controls (4.04±0.46 vs 2.54±0.25 ng/h/µg protein; p<0.05). Reactive oxygen species generation with palmitate was lower in the Pex11ß knockdown cells compared with the scrambled controls (P<0.001). CONCLUSION: Pex11ß knockdown decreased peroxisome abundance, decreased palmitate mediated reactive oxygen species generation, and reversed the inhibitory effect of palmitate on insulin secretion. These findings reveal a distinct role of peroxisomes in palmitate mediated beta-cell dysfunction.


Sujet(s)
Diabète de type 2 , Cellules à insuline/anatomopathologie , Péroxysomes , Animaux , Lignée cellulaire , Diabète de type 2/génétique , Techniques de knock-down de gènes , Glucose , Insuline , Protéines membranaires/génétique , Souris , Palmitates , Espèces réactives de l'oxygène
2.
PLoS One ; 9(12): e115433, 2014.
Article de Anglais | MEDLINE | ID: mdl-25532126

RÉSUMÉ

Type 2 diabetes is characterised by an age-related decline in insulin secretion. We previously identified a 50% age-related decline in mitochondrial DNA (mtDNA) copy number in isolated human islets. The purpose of this study was to mimic this degree of mtDNA depletion in MIN6 cells to determine whether there is a direct impact on insulin secretion. Transcriptional silencing of mitochondrial transcription factor A, TFAM, decreased mtDNA levels by 40% in MIN6 cells. This level of mtDNA depletion significantly decreased mtDNA gene transcription and translation, resulting in reduced mitochondrial respiratory capacity and ATP production. Glucose-stimulated insulin secretion was impaired following partial mtDNA depletion, but was normalised following treatment with glibenclamide. This confirms that the deficit in the insulin secretory pathway precedes K+ channel closure, indicating that the impact of mtDNA depletion is at the level of mitochondrial respiration. In conclusion, partial mtDNA depletion to a degree comparable to that seen in aged human islets impaired mitochondrial function and directly decreased insulin secretion. Using our model of partial mtDNA depletion following targeted gene silencing of TFAM, we have managed to mimic the degree of mtDNA depletion observed in aged human islets, and have shown how this correlates with impaired insulin secretion. We therefore predict that the age-related mtDNA depletion in human islets is not simply a biomarker of the aging process, but will contribute to the age-related risk of type 2 diabetes.


Sujet(s)
ADN mitochondrial/physiologie , Protéines de liaison à l'ADN/antagonistes et inhibiteurs , Diabète de type 2/physiopathologie , Protéines HMG/antagonistes et inhibiteurs , Cellules à insuline/physiologie , Insuline/métabolisme , Mitochondries/physiologie , Adénosine triphosphate/métabolisme , Facteurs âges , Animaux , Technique de Western , Cellules cultivées , ADN mitochondrial/effets des médicaments et des substances chimiques , Protéines de liaison à l'ADN/génétique , Protéines de liaison à l'ADN/métabolisme , Diabète de type 2/traitement médicamenteux , Glucose/pharmacologie , Protéines HMG/génétique , Protéines HMG/métabolisme , Humains , Sécrétion d'insuline , Cellules à insuline/cytologie , Cellules à insuline/effets des médicaments et des substances chimiques , Souris , Mitochondries/effets des médicaments et des substances chimiques , ARN messager/génétique , Réaction de polymérisation en chaine en temps réel , RT-PCR , Édulcorants/pharmacologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...